Lorem ipsum dolor sit amet, consectetur adipiscing elit

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum

Lorem ipsum

Lorem ipsum dolor sit amet

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris. Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris.

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris.

The unmet clinical need

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris.Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris.

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris.

Lorem ipsum dolor sit
amet, consectetur ad
ipisicing elit, sed do
eiusmod tempor incididunt
ut labore et
dolore magna aliqua. Ut enim ad min
im veniam, quis nostrud exercitation ullamco laboris.

Latest press releases

Annexin completes patient enrolment in the NEXUS study – multiple key clinical and regulatory milestones ahead

Annexin Pharmaceuticals AB today announces that the final planned patient in its Phase 2a NEXUS study is receiving treatment, marking the completion of patient enrolment. The patient is the last…

Latest press releases

First patient treated with vanexin following anti-VEGF injection in the NEXUS study

Annexin Pharmaceuticals AB announces that the first patient in the expanded patient cohort of the NEXUS study has now been treated according to the new study design. The patient, diagnosed…

Latest press releases

Annexin advances the NEXUS study to include patients who received an anti-VEGF injection

Annexin Pharmaceuticals AB announces a next patient cohort in the NEXUS study. The company continues to study the effects of the drug candidate vanexin (formerly ANXV) in patients with retinal…

Latest press releases

Annexin Pharmaceuticals receives the International Nonproprietary Name (INN) vanexin for the drug candidate ANXV

Annexin Pharmaceuticals AB today announces that the World Health Organization (WHO) has selected vanexin as the proposed International Nonproprietary Name (INN) for the company's drug candidate ANXV. It is an…